Harbour BioMed and BioMap Announce Strategic Partnership to Launch MegaStream TechBio, an AI-Powered Biologics Drug Discovery Company

▎Armstrong

On June 15, 2026, Harbour BioMed and BioMap announced the establishment of a comprehensive, multi-tiered, long-term strategic partnership to conduct full-spectrum collaboration on the AI-driven research and development of complex biologic drugs.，Aimed at systematically overcoming the bottlenecks and challenges in the research and development of next-generation innovative therapies, jointly building a globally competitive R&D ecosystem.

This collaboration marks a milestone in AI-driven macromolecular drug development. As we enter a new era of AI-enabled drug discovery, the core challenge lies in determining what to pursue and how to execute it; this collaborative framework provides a new direction.

First, what to do?

Targeting major unmet clinical needs in cardiovascular, renal, central nervous system, anti-aging, and metabolic diseases,With FIC and BIC as the Core Benchmarks, develop next-generation cutting-edge complex macromolecular drugs with global competitiveness,Accelerate the Differentiated Innovation Pipeline in BulkEntering the clinical stage, committed to becoming a globally leading benchmark enterprise in AI-driven drug R&D for complex macromolecules.

It is evident that this collaboration focuses on chronic disease indications. Cardiovascular, renal, and metabolic (CVRM) disorders, central nervous system (CNS) conditions, and anti-aging therapies are all health issues that broadly impact human well-being, address significant unmet clinical needs, and represent areas where multinational corporations (MNCs) and biotech companies are most actively investing. Statistics show that over 2 billion people worldwide suffer from chronic diseases, and by 2040, the top five causes of death will include cardiovascular disease, chronic obstructive pulmonary disease (COPD), and chronic kidney disease. Aging is highly correlated with chronic diseases; by 2030, individuals aged over 60 will account for one-sixth of the global population, with up to 98% of elderly individuals suffering from multiple chronic conditions. From a socio-economic perspective, chronic diseases cause 24 million deaths annually, and the economic burden attributable to chronic diseases is projected to reach $22 trillion by 2030.

In May this year,Harbour BioMed’s disclosure of preclinical data for LET003, its first AI-discovered candidate drug—an ActRIIA/B antibody—serves as a vivid example of the aforementioned strategic rationale. The data demonstrate that LET003 exhibits superior pharmacokinetic properties,Low doses can achieve effects comparable to high-dose Bimagrumab in promoting lean body mass gain. When used in combination with semaglutide, it significantly enhances fat loss while effectively preserving lean body mass, demonstrating its potential to become a best-in-class (BIC) therapy for obesity treatment.

Obesity and overweight have become high-risk factors for various chronic diseases, and the potential best-in-class ActRIIA/B antibody is expected to provide better therapeutic options for weight loss. This collaboration will batch-develop similar differentiated innovative pipelines, setting a new paradigm-level benchmark for AI applications across the industry.

Second, how to do it?

With clear objectives in place, the next step is implementation. In accordance with the strategic cooperation framework, both parties will jointly establish a novel AI-driven pipeline R&D company targeting the global market—MegaStream TechBio。As the lead initiator, Harbour BioMed opens access to its globally unique, non-exclusive fully human antibody platform, deep target biology expertise, and global clinical development advantages.BioMap, as a co-initiator,Provides underlying AI technology empowerment, model engineering support, and intelligent R&D capabilities.The initial pipeline comprises both AI-driven drug discovery projects from the parties’ prior collaborations and newly initiated AI-native pipeline development projects. The initiating parties shall be entitled to potential upfront payments, success-based milestones, and royalty shares in accordance with industry standards.MegaStream’s core management team will be jointly formed by senior executives from multinational pharmaceutical companies and top experts in the field of artificial intelligence, with relevant personnel gradually assuming their positions.

Through this strategic alliance, MegaStream TechBio will emerge as a pivotal innovation hub for macromolecular drugs targeting chronic diseases, demonstrating comprehensive competitive advantages.

First, Harbour BioMed's proprietaryBased on nearly 10 million NGS data entries with independent intellectual property rightsHCAb SeriesUnderlying data and vast public databases serve as the robust data foundation for AI-driven macromolecular drug discovery.BioMap leverages its capabilities in foundational large models for life sciences,In response to the distinct characteristics of complex macromolecular drugs compared to conventional generic protein and antibody therapeutics, we conduct systematic, targeted training, optimization, and iteration to develop a personalized, proprietary MegaStream large model with continuous self-evolution capabilities.

Secondly, based on the MegaStream large model, both parties will combine Harbour BioMed’s extensive proprietary experimental technical capabilities with BioMap OS, BioMap’s discovery system featuring high-throughput dry-wet closed-loop laboratory scheduling management and automated dataLeveraging strengths in analysis, data management, and model iteration to build a next-generation intelligent high-throughput closed-loop dry-wet laboratory,Establish a fully automated closed-loop "Design-Build-Test-Learn" chain.Efficiency is projected to increase by over 500% compared to the previous generation of dry-wet closed-loop laboratories. The laboratory will enhance data accumulation efficiency by more than 10-fold, generating over 5 PB of high-quality AI-ready life science data within the next five years, thereby driving the rapid and effective evolution of AI models.

Ultimately, this collaboration centers on clinical value and will concurrently advance hundreds of innovative pipelines. By employing AI model predictions supplemented with a small number of high-precision validations to replace traditional repetitive screening experiments, and leveraging the generative predictive advantages of large language models, we will generate high-caliber pipeline molecules with superior performance metrics, more comprehensive property optimization, and more precise programmable controllability. This ushers in a new era of scaled, efficient R&D for First-in-Class (FIC) and Best-in-Class (BIC) therapeutics.

Summary

Over the past two years, Harbour BioMed and AstraZeneca,The collaborations between Innovent Biologics and Eli Lilly, Hengrui Medicine and Bristol Myers Squibb, as well as Innovent Biologics and Pfizer, exemplify the high recognition by multinational corporations (MNCs) of the high-efficiency, low-cost drug R&D systems of Chinese pharmaceutical companies. The current partnership between Harbour BioMed and BioMap leverages Harbour BioMed’s extensive foundation of high-quality large-molecule drug data and BioMap’s capabilities in biological science large models to fully AI-enable and establish a dry-wet closed loop for chronic disease large-molecule drug development. This approach facilitates continuous iteration and the batch advancement of the R&D and clinical development of hundreds of large-molecule drugs, providing a full-process solution platform for the global biopharmaceutical industry.